替米沙坦治疗对淋巴结或脂肪组织纤维化的改善不优于继续单用抗逆转录病毒治疗
这项48周随机对照试验纳入44名接受HIV抑制性抗逆转录病毒治疗的成人,比较加用替米沙坦与不加药对淋巴结和脂肪组织纤维化的影响。结果显示继续单用抗逆转录病毒治疗即可使淋巴结和脂肪组织纤维化下降,加用替米沙坦未带来额外纤维化改善。
要点
- 48周内继续单用抗逆转录病毒治疗可使淋巴结和脂肪组织纤维化下降。
- 加用替米沙坦未在淋巴结或脂肪组织纤维化改善上优于单用抗逆转录病毒治疗。
- 替米沙坦对纤连蛋白沉积增加的减弱作用P=0.06,未达统计学显著。
核心结论
- 在接受治疗的HIV感染成人中,继续单用抗逆转录病毒治疗可使淋巴结和脂肪组织纤维化下降,加用替米沙坦未带来额外纤维化改善。
研究设计与样本
- 48周随机对照试验,成人继续HIV抑制性抗逆转录病毒治疗并接受替米沙坦或无药物,共44人入组。
- 35人有配对脂肪组织标本,29人有配对淋巴结标本,第0周和第48周用免疫组化定量胶原I、纤连蛋白、磷酸化SMAD3及胶原VI沉积。
- 采用双侧秩和检验和符号秩检验比较48周变化。
主要发现
- 淋巴结标本中胶原I沉积面积百分比总体中位变化为-2.6个百分点(P=0.08),脂肪组织标本为-1.3个百分点(P=.001),两组间无差异。
- 淋巴结标本中pSMAD3沉积总体变化为-0.5个百分点(P=.04),两组间无差异。
- 替米沙坦减弱纤连蛋白沉积增加(P=.06)。
- 脂肪组织中胶原VI沉积变化为-1.0个百分点(P=.001),纤连蛋白沉积变化为-2.4个百分点(P<.001),两组间无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 44人入组,仅35人有配对脂肪组织标本、29人有配对淋巴结标本。
- 替米沙坦减弱纤连蛋白沉积增加的P值为.06,未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibrosis in lymph nodes may limit CD4+ T-cell recovery, and lymph node and adipose tissue fibrosis may contribute to inflammation and comorbidities despite antiretroviral therapy (ART). We hypothesized that the angiotensin receptor blocker and peroxisome proliferator-activated receptor γ agonist telmisartan would decrease lymph node or adipose tissue fibrosis in treated human immunodeficiency virus type 1 (HIV) infection. METHODS: In this 48-week, randomized, controlled trial, adults continued HIV-suppressive ART and received telmisartan or no drug. Collagen I, fibronectin, and phosphorylated SMAD3 (pSMAD3) deposition in lymph nodes, as well as collagen I, collagen VI, and fibronectin deposition in adipose tissue, were quantified by immunohistochemical analysis at weeks 0 and 48. Two-sided rank sum and signed rank tests compared changes over 48 weeks. RESULTS: Forty-four participants enrolled; 35 had paired adipose tissue specimens, and 29 had paired lymph node specimens. The median change overall in the percentage of the area throughout which collagen I was deposited was -2.6 percentage points (P = 0.08) in lymph node specimens and -1.3 percentage points (P = .001) in adipose tissue specimens, with no between-arm differences. In lymph node specimens, pSMAD3 deposition changed by -0.5 percentage points overall (P = .04), with no between-arm differences. Telmisartan attenuated increases in fibronectin deposition (P = .06). In adipose tissue, changes in collagen VI deposition (-1.0 percentage point; P = .001) and fibronectin deposition (-2.4 percentage points; P < .001) were observed, with no between-arm differences. CONCLUSIONS: In adults with treated HIV infection, lymph node and adipose tissue fibrosis decreased with continued ART alone, with no additional fibrosis reduction with telmisartan therapy.
引用
- Utay NS, Kitch DW, Yeh E, et al. Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone. J Infect Dis. 2018. PMID: 29401318. doi:10.1093/infdis/jiy064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。